Last reviewed · How we verify
MK0928, gaboxadol
Gaboxadol is a selective GABA-A receptor agonist that enhances inhibitory neurotransmission in the central nervous system.
Gaboxadol is a selective GABA-A receptor agonist that enhances inhibitory neurotransmission in the central nervous system. Used for Insomnia, Anxiety disorders.
At a glance
| Generic name | MK0928, gaboxadol |
|---|---|
| Sponsor | H. Lundbeck A/S |
| Drug class | GABA-A receptor agonist |
| Target | GABA-A receptor (delta subunit-containing) |
| Modality | Small molecule |
| Therapeutic area | Neurology / Sleep Medicine |
| Phase | Phase 3 |
Mechanism of action
Gaboxadol selectively activates extrasynaptic GABA-A receptors containing the delta subunit, which are thought to mediate tonic inhibition in the brain. This mechanism differs from traditional benzodiazepines and may provide anxiolytic and sleep-promoting effects with potentially improved tolerability and reduced abuse potential.
Approved indications
- Insomnia
- Anxiety disorders
Common side effects
- Dizziness
- Somnolence
- Headache
- Nausea
Key clinical trials
- Safety of MK0928 on Insomnia in the Elderly (0928-005)(COMPLETED) (PHASE3)
- Adult Primary Insomnia Polysomnographic Study (0928-004)(COMPLETED) (PHASE3)
- Efficacy and Safety of MK0928 for Insomnia in Adults (0928-003)(COMPLETED) (PHASE3)
- An Investigational Study of MK0928 in Adult Outpatients With Insomnia (0928-014)(COMPLETED) (PHASE3)
- Study of MK0928 in Healthy Adult Volunteers in a Model of Insomnia (0928-006)(COMPLETED) (PHASE3)
- Sleep Laboratory Study of MK0928 in Adult Patients With Primary Insomnia (0928-041)(TERMINATED) (PHASE2)
- An Investigational Drug Study in Healthy Adult Volunteers in a Model of Insomnia (0928-007) (PHASE3)
- Elderly Primary Insomnia Polysomnographic Study (0928-002)(TERMINATED) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MK0928, gaboxadol CI brief — competitive landscape report
- MK0928, gaboxadol updates RSS · CI watch RSS
- H. Lundbeck A/S portfolio CI